Milk Sugar Plus Infant Probiotic Team Up to Crush Gut Inflammation
3'-Sialyllactose and B. infantis synergistically reduced colitis severity by boosting SCFA-producing gut bacteria through cross-feeding mechanisms.
Summary
Researchers tested whether combining 3'-sialyllactose (3'-SL), a human milk oligosaccharide, with Bifidobacterium infantis could treat colitis better than either alone. In DSS-induced colitis mice, the combination outperformed single treatments by restoring gut microbiota balance, raising short-chain fatty acid (SCFA) levels, strengthening the gut barrier, and reducing inflammatory cytokines. The key mechanism was cross-feeding: B. infantis broke down 3'-SL into simpler sugars that other beneficial bacteria then used to produce SCFAs like butyrate. The synbiotic reduced disease activity scores, prevented colon shortening, restored goblet cells, and upregulated tight junction proteins ZO-1, occludin, and claudin-1. These findings suggest that pairing specific prebiotics with compatible probiotics may offer a safer, targeted strategy for managing inflammatory bowel disease.
Detailed Summary
Ulcerative colitis (UC) affects millions globally and remains difficult to treat with conventional therapies. This study from Zhejiang University explored whether combining 3'-sialyllactose (3'-SL), a sialylated human milk oligosaccharide abundant in breast milk, with Bifidobacterium longum subsp. infantis (B. infantis) EVC001 could synergistically treat UC better than either agent alone. The rationale was mechanistically grounded: B. infantis uniquely encodes gene clusters (H1–H5) that fully metabolize HMOs, and 3'-SL acts as a prebiotic substrate that selectively enriches Bifidobacterium while also serving as a decoy receptor against pathogen adhesion.
The study used a two-phase mouse model design. A dose-optimization phase tested 3'-SL at 12.5, 25, and 50 mg/day and B. infantis at 1×10⁸, 1×10⁹, and 1×10¹⁰ CFU/day in DSS-induced colitis male C57BL/6J mice (n=8/group). The functional phase (n=6/group) then compared control, model, 3'-SL alone (25 mg/day), B. infantis alone (1×10¹⁰ CFU/day), and synbiotic (both combined) groups. DSS (3% w/v) was administered in drinking water during the final week of each three-week protocol. Outcomes included disease activity index (DAI), colon length, histopathology, PAS staining for goblet cells, immunofluorescence for tight junction proteins, 16S rRNA gut microbiota profiling, SCFA quantification, and serum cytokine panels.
All three active treatments (3'-SL, B. infantis, synbiotic) significantly reduced DAI scores and prevented colon shortening compared to DSS-only controls. However, the synbiotic treatment consistently outperformed individual arms. Histopathological analysis showed significantly less colonic mucosal damage with synbiotic treatment, while PAS staining revealed restored goblet cell counts and glycoprotein content in crypt cells. Immunofluorescence confirmed that synbiotic treatment upregulated tight junction proteins ZO-1, occludin, and claudin-1 to near-control levels. Serum cytokine analysis demonstrated that the synbiotic reduced pro-inflammatory markers (TNF-α, IL-6, IL-1β) while elevating anti-inflammatory IL-10 more effectively than either component alone.
The microbiota data were particularly compelling. 16S rRNA sequencing showed that the synbiotic treatment produced the greatest restoration of microbiota diversity and composition. The combination enriched SCFA-producing bacteria beyond what B. infantis or 3'-SL alone achieved, with notable increases in Lactobacillus, Akkermansia, and butyrate-producing Firmicutes. Fecal SCFA quantification confirmed significantly elevated acetate, propionate, and butyrate levels in the synbiotic group. The proposed mechanism is cross-feeding: B. infantis catabolizes 3'-SL into simpler monosaccharides (including sialic acid, galactose, and glucose), which are then consumed by other commensal bacteria that produce SCFAs. This ecosystem-level cooperation explains why the combination exceeds additive effects.
The study provides a mechanistic framework for synbiotic therapy in UC and broader gut inflammatory disorders. The use of a human milk-derived prebiotic paired with a naturally co-evolved probiotic mirrors infant gut biology and may offer a physiologically intuitive therapeutic axis. Limitations include exclusive use of a mouse model, all-male subjects, and a relatively short one-week DSS induction window. Translation to human UC, particularly in adults with a very different baseline microbiome, will require clinical validation.
Key Findings
- Synbiotic (3'-SL + B. infantis) produced significantly lower DAI scores than either agent alone in DSS-induced colitis mice
- Synbiotic treatment restored goblet cell counts and crypt glycoprotein content to near-control levels per PAS staining
- Tight junction proteins ZO-1, occludin, and claudin-1 were all upregulated with synbiotic treatment, indicating restored gut barrier integrity
- Fecal SCFA levels (acetate, propionate, butyrate) were highest in the synbiotic group, surpassing individual 3'-SL and B. infantis groups
- 16S rRNA sequencing confirmed the synbiotic produced the greatest restoration of microbiota diversity, enriching Akkermansia and butyrate-producing Firmicutes
- Serum pro-inflammatory cytokines TNF-α, IL-6, and IL-1β were most reduced in the synbiotic group while anti-inflammatory IL-10 was most elevated
- B. infantis EVC001 demonstrated in vitro capacity to utilize 3'-SL as a sole carbohydrate source, confirming the cross-feeding metabolic mechanism
Methodology
Two-phase experiment using DSS-induced colitis in male SPF C57BL/6J mice (6–7 weeks old); dose-optimization phase used n=8/group across 8 groups, functional phase used n=6/group across 5 groups. Three-week gavage protocol with 3% DSS in drinking water during the final week. Outcomes assessed via DAI scoring, colon length, H&E and PAS histopathology, immunofluorescence, 16S rRNA sequencing, GC-MS SCFA quantification, and ELISA cytokine panels.
Study Limitations
The study was conducted entirely in a mouse model using a short-duration chemical colitis induction (1-week DSS), which may not fully recapitulate the chronic, relapsing nature of human UC. All mice were male, limiting generalizability to female subjects. No conflicts of interest were declared, but 3'-SL was sourced from Glycom A/S (Denmark) and B. infantis from Infinant Health (USA), introducing potential supplier relationships.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: